Search results for "aav"

Article Top Challenges to Overcome When Developing AAV Processes: Part 1 of 2
Watch the Q&A interview >> In the first of a two-part series, Anki Magnusson, Staff Research Engineer, Protein and Viral Production, and Åsa Hagner-McWhirter, PhD, Senior Scientist…

Article How to Optimize and Scale Up AAV Production
In this article from a roundtable discussion, four experts from academia and industry met to discuss challenges in refining and scaling up AAV production pipelines to meet the increasing demand for …

Article Future-proof your AAV process with a complete producer cell line – just induce and grow
To deliver on the promise of AAV-based gene therapy for prevalent diseases, we need similar technology. The challenge is that multiple genetic elements – rep, helper, capsid, and gene of interest – mu…

Article Gene Therapies Push Viral Vector Production
By Feliza Mirasol  Several virus types have been studied for use as viral vectors in gene therapy, including adenovirus, lentivirus, retrovirus, and adeno-associated virus (AAV). Of these, AA…

Article A Look at the Affinity Chromatography Landscape
The greatest demand is for lentiviral and adeno-associated viral (AAV) vectors, with sourcing of lentiviral vectors becoming a bottleneck for gene and cell therapy manufacturing. Traditionally,…

Article Single-Use Technologies Prove Effective for Viral Vector Process Development
Notably for the manufacture of vectors based on adeno-associated virus (AAV), one of the most common vector types for gene therapy delivery and viral-vector vaccines, recent data have shown that stain…

Article Scaling Up Novel Therapies
Great improvements have been seen so far in delivering adeno-associated virus (AAV) vectors. These results demonstrate the inextricable link between clinical work and process development, said Kathy H…

Article Report from the 6th International HTPD Conference
Beyond mAbs: AAV and mRNA process development were discussed at HTPD 2023 Since the clinical pipeline is becoming more and more diversified, novel types of biomolecules have also become more in…

Article How to develop a scalable rAAV process
Here we present the latest updates to our work developing a scalable start-to-finish rAAV process. We produce and purify several serotypes, optimizing each step along the way. The key for a successful…

Article Top Process Development Trends for 2021 and a Look into 2022
However, the focus in 2021 shifted beyond the pandemic to optimization and scaling up adeno-associated virus (AAV) production, process workflows and considerations for messenger RNA (mRNA) therapeutic…

Previous PageNext Page